Literature DB >> 7673148

Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.

G A Nicolaes1, G Tans, M C Thomassen, H C Hemker, I Pabinger, K Varadi, H P Schwarz, J Rosing.   

Abstract

Factor V was purified from the plasma of an activated protein C (APC)-resistant patient who is homozygous for the mutation Arg506-->Gln (factor VR506Q). Factor VR506Q was converted by thrombin into factor Va which was further purified yielding a factor Va preparation that had the same cofactor activity in prothrombin activation as normal factor Va. Inactivation of low concentrations of normal factor Va (< 5 nM) by 0.15 nM APC in the presence of phospholipid vesicles proceeded via a biphasic reaction that consisted of a rapid phase (k = 4.3 x 10(7) M-1s-1), yielding a reaction intermediate with reduced cofactor activity that was fully inactivated during the subsequent slow phase (k = 2.3 x 10(6) M-1s-1). Inactivation of factor VaR506Q proceeded via a monophasic reaction (k = 1.7 x 10(6) M-1s-1). Immunoblot analysis showed that APC-catalyzed inactivation of factor Va occurred via peptide bond cleavages in the heavy chain. The rapid phase of inactivation of normal factor Va was associated with cleavage at Arg506 and full inactivation of factor Va required subsequent cleavage at Arg306. The slow monophasic inactivation of factor VaR506Q correlated with cleavage at Arg306. Cleavage at Arg506 in normal factor Va resulted in accumulation of a reaction intermediate that exhibited 40% cofactor activity in prothrombin activation mixtures that contained a high factor Xa concentration (5 nM). Compared with native factor Va, the reaction intermediate retained virtually no cofactor activity at low factor Xa concentrations (0.3 nM). This demonstrates that factor Va that is cleaved at Arg506 is impaired in its ability to interact with factor Xa. Michaelis-Menten kinetic analysis showed that cleavage at Arg506 in membrane-bound factor Va was characterized by a low Km for factor Va (20 nM) and kcat = 0.96 s-1. For cleavage at Arg306 in factor VaR506Q the kinetic parameters were Km = 196 nM and kcat = 0.37 s-1. This means that differences between APC-catalyzed inactivation of factors Va and VaR506Q become much less pronounced at high factor Va concentrations. When factor VaR506Q was inactivated by APC in the absence of phospholipids, cleavage at Arg679 of the heavy chain also contributed to factor Va inactivation. Comparison of rate constants for APC-catalyzed cleavage at Arg306, Arg506, and Arg679 in the absence and presence of phospholipids indicated that phospholipids accelerated these cleavages to a different extent.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673148     DOI: 10.1074/jbc.270.36.21158

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Prothrombotic phenotype of protein Z deficiency.

Authors:  Z F Yin; Z F Huang; J Cui; R Fiehler; N Lasky; D Ginsburg; G J Broze
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Authors:  Thomas J Cramer; John H Griffin; Andrew J Gale
Journal:  Pathophysiol Haemost Thromb       Date:  2010-05-22

3.  The functional significance of the autolysis loop in protein C and activated protein C.

Authors:  Likui Yang; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

4.  Gly74Ser mutation in protein C causes thrombosis due to a defect in protein S-dependent anticoagulant function.

Authors:  Changming Chen; Likui Yang; Bruno O Villoutreix; Xuefeng Wang; Qiulan Ding; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2017-04-13       Impact factor: 5.249

5.  The Journey of Protein S from an Anticoagulant to a Signaling Molecule.

Authors:  V S Pilli; William Plautz; Rinku Majumder
Journal:  JSM Biochem Mol Biol       Date:  2016-08-08

6.  Gly197Arg mutation in protein C causes recurrent thrombosis in a heterozygous carrier.

Authors:  Yeling Lu; Hemant Giri; Bruno O Villoutreix; Qiulan Ding; Xuefeng Wang; Alireza R Rezaie
Journal:  J Thromb Haemost       Date:  2020-04-09       Impact factor: 5.824

7.  Phosphorylation of protein S by platelet kinases enhances its activated protein C cofactor activity.

Authors:  Fabian Stavenuiter; Andrew J Gale; Mary J Heeb
Journal:  FASEB J       Date:  2013-04-11       Impact factor: 5.191

Review 8.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

9.  Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the gamma-carboxyglutamic acid-rich domain.

Authors:  D Borgel; P Gaussem; C Garbay; C Bachelot-Loza; T Kaabache; W Q Liu; B Brohard-Bohn; B Le Bonniec; M Aiach; S Gandrille
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

10.  The role of thrombin exosites I and II in the activation of human coagulation factor V.

Authors:  Kenneth Segers; Björn Dahlbäck; Paul E Bock; Guido Tans; Jan Rosing; Gerry A F Nicolaes
Journal:  J Biol Chem       Date:  2007-09-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.